This profile is for educational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting any compound.
What Is TB-500?
TB-500 is a synthetic peptide corresponding to the actin-binding domain of Thymosin Beta-4 (TĪ²4), a naturally occurring 43-amino-acid protein found in virtually all human cells. Specifically, TB-500 is the 17ā23 amino acid fragment of TĪ²4 ā the portion responsible for most of the parent molecule's tissue-repair and anti-inflammatory activity. Full Thymosin Beta-4 is present at high concentrations in wound fluid and platelets, where it acts as a master regulator of cellular repair responses following tissue injury.
The key distinction between TB-500 and BPC-157 is their operational scope. BPC-157 tends to exert strong local effects when injected near a site of injury, making it excellent for targeting a specific tendon, ligament, or gut region. TB-500, by contrast, distributes widely throughout the body after subcutaneous injection, enabling it to address multiple injury sites simultaneously and support systemic regenerative processes. This difference in action radius is why the combination of the two peptides has become so well-regarded in recovery-focused biohacking communities.
TB-500 is used in equine veterinary medicine (notably for race horses) under the name Thymosin Beta-4, which provided an early real-world dataset for its effects on musculoskeletal repair. The World Anti-Doping Agency (WADA) has prohibited its use in competitive sport, reflecting how significant its performance-enhancement and recovery properties are considered to be. It is sold as a research chemical in the United States and many other countries.
How It Works
TB-500's primary biochemical action is the sequestration of G-actin (monomeric actin), a critical cytoskeletal protein. By binding G-actin at a 1:1 ratio, TB-500 effectively controls the local concentration of free actin in cells, which has downstream effects on cell shape, migration speed, and division. This regulation of actin dynamics is essential for the rapid migration of repair cells ā fibroblasts, endothelial cells, keratinocytes ā into damaged tissue zones. Without sufficient actin availability and mobility, these cells cannot traverse the injury site effectively, slowing repair.
Beyond actin binding, TB-500 potently promotes angiogenesis through upregulation of VEGF (vascular endothelial growth factor) and related signaling molecules. New blood vessel formation is not merely a cosmetic aspect of repair ā it delivers oxygen, nutrients, and immune cells to previously ischemic tissue, enabling full structural regeneration rather than fibrotic scarring. TB-500 also suppresses NF-ĪŗB, a master transcription factor for inflammatory gene expression, reducing the production of pro-inflammatory cytokines that would otherwise prolong the destructive phase of the inflammatory response and impair healing.
Research has also highlighted TB-500's effects on cardiac tissue. In animal models of heart attack, TĪ²4 and its fragments have demonstrated the ability to activate resident cardiac progenitor cells and promote partial regeneration of damaged myocardium ā a finding that has generated significant interest in cardiovascular medicine circles, where the heart's limited regenerative capacity remains a major clinical challenge.
Key Benefits Discussed in Research
Dosing Reference (Educational Only)
All dosing information is derived from preclinical research and anecdotal community experience. Work with a qualified physician before starting any protocol.
| Parameter | Common Research Range | Notes |
|---|---|---|
| Loading Dose | 2ā5 mg, 2Ć per week | Loading phase: first 4ā6 weeks, for active injuries or initial protocol |
| Maintenance Dose | 2 mg per week | After loading phase; for ongoing systemic support or injury prevention |
| Cycle Length | 4ā6 weeks loading, then maintenance or cycle off | Some protocols run 8 weeks total before a break |
| Route | SubQ injection | Abdominal SubQ is standard; near-injury injection also used |
| Reconstitution | Bacteriostatic water (2ml per 5mg vial) | Refrigerate reconstituted solution; use within 30 days |
| Timing | No specific timing requirement | Not dependent on food intake; morning injection is common practice |
Want the Full TB-500 Protocol?
Join SDBioHack and access community-validated protocols, sourcing checklists, and expert Q&A.
Side Effects & Safety Profile
TB-500 has a generally well-tolerated profile based on animal research and community self-experimentation data. The most commonly reported side effects are injection site reactions including mild redness, tenderness, or swelling ā typical of any subcutaneous peptide injection. Some users report a brief period of fatigue or flu-like symptoms at the start of a loading protocol, which generally resolves within a few days. Headache has also been occasionally noted. These effects tend to be dose-dependent and more prominent during loading phases.
Because TB-500 promotes angiogenesis and cell migration, the same theoretical concern raised with BPC-157 applies here: in the presence of pre-existing malignancy, these proliferative mechanisms could theoretically be counterproductive. No clinical human trials specifically evaluating TB-500's safety and efficacy in humans have been completed, meaning all safety conclusions are extrapolated from animal studies and self-reported community data. This gap in human data is important to acknowledge when evaluating risk.
- History of cancer or active malignancy: avoid use due to pro-angiogenic and pro-proliferative activity.
- Pregnancy and breastfeeding: no safety data available; avoid.
- WADA-prohibited substance: competitive athletes subject to drug testing must not use TB-500.
- Always source from reputable suppliers with third-party certificates of analysis to reduce contamination risk.
Common Stacks & Pairings
The BPC-157 + TB-500 stack is arguably the most discussed healing combination in the biohacking world. The rationale is straightforward: BPC-157 provides potent local repair signals at the injury site, while TB-500 delivers systemic actin-regulating and angiogenic support throughout the body. Together they cover both the local and systemic dimensions of tissue repair. GHK-Cu is sometimes added to provide collagen and extracellular matrix synthesis support. For athletes managing multiple soft-tissue injuries, this triple stack is frequently mentioned in community forums.
Frequently Asked Questions
Full Thymosin Beta-4 (TĪ²4) is a 43-amino acid protein; TB-500 is specifically the 17ā23 fragment (LKKTETQ) that contains the actin-binding domain responsible for most of TĪ²4's biological activity. TB-500 is significantly less expensive to synthesize and is more widely available than the full-length peptide. Research suggests the fragment retains most of the parent compound's healing and anti-inflammatory properties, though full TĪ²4 has some additional immunomodulatory functions not fully replicated by the fragment alone.
WADA classifies TB-500 under the category of peptide hormones, growth factors, related substances, and mimetics ā a broad category prohibiting compounds that can enhance physical performance or accelerate recovery. The prohibition reflects that TB-500's tissue repair and anti-inflammatory effects could provide meaningful competitive advantages in athletic recovery. Athletes in any WADA-governed sport who use TB-500 risk disqualification, even if the compound is not legally controlled in their country of residence.
Standard loading protocols typically run 4ā6 weeks with 2ā5 mg administered twice per week. Many users report measurable improvements in pain, range of motion, and functional capacity within the first 2ā3 weeks of loading. For chronic, long-standing injuries, the timeline may extend to 6ā8 weeks before significant changes are apparent. Following the loading phase, a maintenance dose of approximately 2 mg per week is often used to sustain the benefits and continue gradual repair.
TB-500's systemic distribution means injection location is less critical than with locally acting peptides like BPC-157. Standard practice is subcutaneous injection in the abdomen, which is convenient and well-absorbed. Some users also inject near the injury site for a theoretical localized boost, though the evidence base for site-specific advantages over TB-500 is thinner than for BPC-157. The key priority is consistent administration at the correct dose, regardless of exact injection location.
The most common community protocol involves administering both simultaneously. BPC-157 is typically dosed daily at 250ā500 mcg, while TB-500 is dosed 2ā3 times per week during the loading phase. They can be injected at the same time in separate syringes or at different times of day ā no interaction concerns have been identified. Some practitioners prefer to run BPC-157 continuously and cycle TB-500 in 4ā6 week loading blocks with maintenance phases in between.
Goldstein AL, et al. "Thymosin beta-4: A multi-functional regenerative peptide." Expert Opinion on Biological Therapy. 2012;12(Suppl 1):S37ā51.
Philp D, et al. "Thymosin beta-4 induces hair growth via stem cell migration and differentiation." Annals of the New York Academy of Sciences. 2004;1051:413ā418.
Bock-Marquette I, et al. "Thymosin beta-4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair." Nature. 2004;432(7016):466ā472.
Smart N, et al. "Thymosin beta-4 induces adult epicardial progenitor mobilization and neovascularization." Nature. 2007;445(7124):177ā182.
Xu B, et al. "Thymosin beta-4 reduces myocardial infarct size and improves cardiac function." Journal of Cardiovascular Pharmacology. 2009;53(2):160ā165.